Cue Biopharma Inc. (CUE)
1.22
-0.12 (-8.96%)
At close: Jan 14, 2025, 3:59 PM
1.22
0.00%
After-hours Jan 14, 2025, 07:32 PM EST
undefined% (undefined)
| Bid | 0.94 |
| Market Cap | 77.29M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.91 |
| PE Ratio (ttm) | -1.34 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.87 |
| Volume | 400,729 |
| Avg. Volume (20D) | 595,262 |
| Open | 1.33 |
| Previous Close | 1.34 |
| Day's Range | 1.20 - 1.37 |
| 52-Week Range | 0.45 - 3.03 |
| Beta | undefined |
About CUE
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-10...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 2, 2018
Employees 53
Stock Exchange NASDAQ
Ticker Symbol CUE
Website https://www.cuebiopharma.com
Analyst Forecast
According to 5 analyst ratings, the average rating for CUE stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 227.87% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Cue Biopharma Inc. is scheduled to release its earnings on Mar 10, 2025,
during market hours.
Analysts project revenue of $1.70M, reflecting a -6.64% YoY shrinking and earnings per share of -0.14, making a -51.72% decrease YoY.
Analysts project revenue of $1.70M, reflecting a -6.64% YoY shrinking and earnings per share of -0.14, making a -51.72% decrease YoY.
2 months ago ·
Source
-16.67%
Cue Biopharma shares are trading lower. The compan...
Unlock content with
Pro Subscription
3 months ago ·
Source
+49.61%
Cue Biopharma shares are trading higher. The company annonunced it priced its $12 million public offering.
